Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.41 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18626429 | 0.91 | MME (0.49) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL16930474 | 0.91 | MME (0.46) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL18874860 | 0.88 | MME (0.49) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL18874739 | 0.86 | MME (0.51) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL18626432 | 0.85 | MME (0.47) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL14919221 | 0.85 | MME (0.52) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL11969895 | 0.85 | MME (0.52) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL20306311 | 0.84 | MME (0.48) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL16930437 | 0.83 | MME (0.48) | MMEPPARGEPHX2MEN1NPC1 | |
| SCHEMBL16930426 | 0.82 | MME (0.59) | MMEPPARGEPHX2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | MME 1/4885PPARG 4858/4885EPHX2 1795/4885 |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885PPARG 4858/4885EPHX2 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.